Mavyret marks the first and only direct-acting antiviral approved to treat both acute and chronic hepatitis C virus ...

The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric patients three years and older with acute ...

This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV.

FDA approves AbbVie's Mavyret for acute hepatitis C, expanding its use to patients 3 and older with or without cirrhosis ...

Mavyret is a fixed dose combination of the direct-acting antiviral agents, glecaprevir, a HCV NS3/4A protease inhibitor, and pibrentasvir, an HCV NS5A inhibitor.

Shares of AbbVie (ABBV) traded over 1% higher on Wednesday after the company announced that the U.S. Food and Drug ...

Hepatitis C virus (HCV) infection is highly associated with the development of metabolic dysfunction-associated steatotic ...

Patients infected with Hepatitis C Virus (HCV) often present with rheumatic symptoms, but its link to rheumatoid arthritis ...

The Hepatitis C Elimination Coalition commends Senators Bill Cassidy (R-LA) and Chris Van Hollen (D-MD) for their bipartisan ...

ASPPH proudly joined public health and medical leaders for a Congressional Briefing on the Hepatitis C Elimination Imperative ...

The culprit is a virus called hepatitis C virus (HCV), which typically gets into a person’s system through direct contact with infected blood. Once inside the body, it hones in on liver cells ...

Six patients were found to have hepatitis C viremia ... The anesthesiology assistant contracted HCV from Patient 1 and subsequently transmitted the virus, during the incubation stage of his ...